Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 55 % of short-term debt in 2026; threshold 65 %.
-
Board fully replaced NBB
No director from three years ago is still active according to annual account 2026.
Financials
Financial year 2026
NEWPHARMA from Liège, company number BE0838666156, closed financial year 2026 with a result of € -711,789 after tax. For that financial year NEWPHARMA recorded revenue of € 218.2 million and equity of € 1.8 million. Compared with financial year 2025, the result moved from € 273,324 to € -711,789. The company made a loss. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on September 21, 2026.
€ 1.8 million
▼ 28% vs 2025
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -711,789
▼ still € 273,324 profit in 2025
Profit after tax over the fiscal year.
€ 1.6 million
▼ 67% vs 2025
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -3.2 million.
People and assets in 2026
14.3
▼ 0.3 vs 2025
Average over the fiscal year, from the social balance sheet.
€ 1.3 million
▲ 8% vs 2025
€ 94,300 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 696
▼ 32% vs 2025
Book value of vehicles, furniture and equipment.
Debts at end 2026
None
No bank loans on the last day of the fiscal year.
€ 30 million
▲ 47% vs 2025
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 50 days on average.
€ 3.8 million
▲ 15% vs 2025
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2024 | 2025 | 2026 | Change 2025 → 2026 | |
|---|---|---|---|---|---|
| Revenue | € 162,841,137 | € 226,234,565 | € 201,846,447 | € 218,188,628 | ▲ 8% |
| Profit after taxes | € -1,387,541 | € -285,239 | € 273,324 | € -711,789 | ▼ € 985,113 |
| Equity | € 2,529,034 | € 2,243,796 | € 2,517,119 | € 1,805,330 | ▼ 28% |
| Total debts | € 23,198,299 | € 27,760,253 | € 24,572,413 | € 34,406,590 | ▲ 40% |
| Cash | € 2,603,972 | € 7,072,310 | € 4,968,208 | € 1,638,025 | ▼ 67% |
| Land & buildings | € 143,783 | € 135,574 | € 126,726 | € 117,879 | ▼ 7% |
| Retained profit | € -2,520,966 | € -2,806,204 | € -2,532,881 | € -3,244,670 | ▼ € 711,789 |
| Balance sheet total | € 26,319,338 | € 30,339,199 | € 27,429,832 | € 36,634,302 | ▲ 34% |
| Employees (FTE) | 15.4 | 14.7 | 14.6 | 14.3 | ▼ 0.3 |
Key figures of NEWPHARMA, fiscal years 2022 to 2026, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2027) expected before 31 October 2027.
What happened to NEWPHARMA?
What happened at NEWPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- GJ lifesciences Management SRL stepped down as director. NBB
- New annual accounts for financial year 2026: loss of € 711,789 (▼ € 985,113 vs 2025). Source: NBB ↗
- MICHAEL HAMELRIJCK became a director. NBB
- STEFAAN VANDAMME stepped down as director. NBB
- STEFAN GOETHAERT became a director. NBB
- KRIS CASTELEIN became a director. NBB
- JO WILLEMYNS became a director. NBB
- STEFAAN VANDAMME became a director. NBB
In short
From € 1.4 million loss in 2022 to € 711,789 loss in 2026.
Paid € 12,254 in corporate taxes since 2022.
Best year ever: 2025, with € 273,324 profit.
Pays suppliers within 50 days on average.
A new publication or filing at NEWPHARMA? We notify you, reason included.
Follow NEWPHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of NEWPHARMA GROUP, Smartvalue comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
NEWPHARMABehind NEWPHARMA are STEFAN GOETHAERT, KRIS CASTELEIN, JO WILLEMYNS and MICHAEL HAMELRIJCK. The shares are held by NEWPHARMA GROUP (100%) and Smartvalue (99.6%). It owns 65% of Apopharma itself.
Directors
According to the 2026 annual accounts
STEFAN GOETHAERT
Director
since 2023
KRIS CASTELEIN
Director
since 2023
JO WILLEMYNS
Director
since 2023
MICHAEL HAMELRIJCK
Director
since 2026
STEFAAN VANDAMME
Director
since 2023 · until 2026
GJ lifesciences Management SRL
Director · represented by GILLES JOURQUIN
Also active at: APOTHEEK BEAUJEAN CENTRUM, NEWPHARMA GROUP, Smartvalue
since 2021 · until 2027
Shareholders
100%
99.6%
Participations
Apopharma
65%
Establishments
Establishment units
Physical locations of this company
Rue Basse-Wez 315/317
4020 Liège
Rue Basse-Wez 315
4020 Liège
Active since 18 August 2011
Rue du Charbonnage 10 box 2
4020 Liège
Active since 13 January 2012
Rue du Charbonnage 9
4020 Liège
Active since 1 October 2021
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
CLOUDFLARENET - Cloudflare, Inc., US
DNS
Cloudflare DNS
Website info
Features
Security
Network
Details
- Company number
- 0838.666.156
- VAT number
- BE 0838.666.156
- Registered office
- Rue Basse-Wez 315/317, 4020 Liège
- Names & denominations
- NEWPHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 22 August 2011
- Peppol
- Active · Active since 3 Sept 2025
- Contact
- newpharma.be
- Activities · NACE
Overige niet-gespecialiseerde detailhandel
Detailhandel via postorderbedrijven of via internet
Detailhandel in farmaceutische producten